Only a handful of places left for our September 2026 cohort. Applications close soonApply now →

MSTA
Your future
starts here.

Medik8

Also known as: medik8, medik 8, medik-8, crystal retinal

A British cosmetic skincare brand (Medik8 Limited, company 03783618), founded 2009 by Elliot Isaacs, sold through both clinics and open retail. Known for retinaldehyde serums and the trademarked CSA Philosophy: vitamin C plus sunscreen by day, vitamin A by night.

Evidence status

Manufacturer-supported

Medik8's retinal concentration ladder and product range are well documented, but no indexed clinical trial of a named Medik8 product was located. Retinaldehyde has independent ingredient-level evidence, while the brand's efficacy claims rely mainly on manufacturer testing and broader retinoid literature rather than published finished-product trials. Undisclosed formulation details and regional regulatory differences limit direct transfer.

What Medik8 is, and the ranges available#

Medik8 is the trading identity of Medik8 Limited, company 03783618. The company was incorporated in 1999 as Pangaea Direct, became Pangaea Laboratories in 2004 and changed to Medik8 Limited in 2023. The brand itself was founded in 2009 by Elliot Isaacs.[3][3, 4, 5]

Control passed from Isaacs to Globe Bidco Limited, an Inflexion acquisition vehicle, in 2021. L'Oréal announced an agreement in June 2025 to acquire a majority stake, with Inflexion retaining a minority and Medik8 joining L'Oréal Luxe. As at August 2026 Companies House still showed Globe Bidco as the active person with significant control, so a completed transfer was not evidenced there.[3, 4][4, 5][3, 4]

The CSA Philosophy—vitamin C plus sunscreen in the morning and vitamin A at night—is a trademarked brand architecture rather than a clinical guideline.[6]

Crystal Retinal contains retinaldehyde at 0.01%, 0.03%, 0.06%, 0.1%, 0.2% and 0.24%; the eye line uses 0.03%, 0.06% and 0.1%. Intelligent Retinol has been listed at 0.3%, 0.6% and 1%, with other retinol formulas and a separate r-Retinoate retinyl-retinoate line. These are chemically distinct actives.[6][6]

Medik8 operates both a professional clinic channel and open consumer retail. “Professional” treatment supply does not make its home-care products medicines.[6, 4]

Use of Medik8 in aesthetic practice#

Medik8 products are cosmetics in Great Britain, regulated under assimilated Regulation (EC) No 1223/2009 by OPSS and Trading Standards. They are not medicines or medical devices, and no UKCA or CE device mark applies.[2]

The EU now caps retinol, retinyl acetate and retinyl palmitate at 0.05% retinol equivalent in body lotion and 0.3% in other cosmetics, with a vitamin A warning and transition dates from November 2025 and May 2027. Retinaldehyde and retinyl retinoate are not among the named substances.[1]

Great Britain had not adopted those caps or warning requirements by August 2026. A 1% retinol cosmetic can therefore remain lawful in GB while exceeding the EU limit. Northern Ireland should not be collapsed into GB because EU rules may apply there.[1, 2]

The UK Intelligent Retinol page showed the 0.3%, 0.6% and 1% serums unavailable on two August 2026 checks. The site did not say whether this reflected stock, reformulation or range rationalisation.[6]

Contraindications and cautions#

The current instructions for the exact Medik8 product govern. Retinaldehyde, retinol, retinyl retinoate, acid peels and vitamin C formulas do not share one contraindication profile.

Medik8 states that it cannot advise on medical conditions such as pregnancy or breastfeeding and generally recommends avoiding vitamin A while pregnant or breastfeeding, with discussion through a GP or midwife. That is manufacturer caution rather than a statutory ban.[6]

Existing prescription retinoid use is a prescriber-led plan; adding or changing a cosmetic retinoid should not be treated as routine retail. Barrier impairment, active dermatitis, significant irritation and procedure timing are assessed against the exact product and device directions.

Clinical uses and the evidence behind them#

CSA regimen

Medik8 reports 96%, 97% and 60% improvement figures from commissioned CSA studies of 30 or 63 people over 12 months. The first figures are participant self-assessments. No laboratory, protocol, registration, full denominator analysis or publication is supplied.[6]

These data may reflect user experience but cannot be independently assessed or compared with a simpler vitamin C, sunscreen and retinoid regimen.

Crystal Retinal and retinaldehyde

No indexed Medik8 product trial was identified. The sole indexed record containing “Medik8” mentions the brand only in a dermatologist's conflict disclosure.[11]

Ingredient-level evidence is more useful. A 2024 systematic review of 25 tretinoin-comparator studies considered retinoid precursors, including retinaldehyde, a reasonable second-line option when tretinoin is not tolerated, while judging most comparative studies poor quality or biased.[7]

A 23-person double-blind split-face trial found vesicle-delivered retinaldehyde 0.05%/0.1% improved most objective measures more than matched retinol over eight weeks, with no adverse events. It tested another delivery system, not Medik8, and both sides improved.[9]

A focused 2022 review called retinaldehyde the most effective cosmetic retinoid on activity-to-tolerance grounds while also concluding that well-designed clinical evidence for common cosmetic retinoids remains inadequate.[8]

Retinyl retinoate and other claims

Medik8's Clinical Studies page names five peer-reviewed retinyl-retinoate papers, but under “Studies on Retinaldehyde” it repeats that same list rather than providing retinaldehyde studies. The brand does cite published literature; the problem is mismatch between molecule or model and the marketed claim.[13]

Selecting a Medik8 product#

Selection begins with molecule, concentration, finished formulation, current jurisdiction and tolerance. A Crystal Retinal percentage cannot be equated numerically with retinol or tretinoin, and no head-to-head data were located for 0.24% retinaldehyde.

The “11 times faster” retinal claim traces to a 1990 study of cell-free cultured-keratinocyte extracts. Retinal converted to retinoic acid at 51.6 pmol/h/mg protein versus 4.49 for retinol, about 11.5-fold. This is real enzyme arithmetic, not clinical onset, visible improvement or a finished Medik8 product result.[12, 6]

Brand-sponsored skincare percentages commonly come from small uncontrolled studies. A separate 2024 32-woman study of another 0.1% retinal serum reported 12% fine-line and 20% pore improvement without a control; it illustrates the design rather than validating Crystal Retinal.[10]

Current manufacturer directions govern frequency, combination and procedure timing. Skinipedia does not publish a CSA or retinoid build-up protocol.

Adverse effects and their management#

Expected local effects

Vitamin A cosmetics may cause dryness, erythema, stinging or peeling. Irritation is not proof of efficacy and should be assessed against barrier condition and the exact formula.

Product differences

Higher percentage does not automatically mean greater clinical effect or tolerability. The published retinaldehyde comparisons lie at 0.05–0.1%, below Medik8's 0.2% and 0.24% products, so their safety cannot simply be transferred upward.[9]

Persistent reactions

Marked inflammation, blistering, allergy, delayed recovery or pigment change requires the product to be stopped and assessed. The exact product, strength, lot, concurrent actives and procedure history should be recorded.

Referral and scope boundaries#

Pregnancy and breastfeeding questions, prescription-retinoid use, moderate-to-severe acne, suspected dermatitis and significant reactions require appropriate clinical or prescriber input.[6]

Medik8 cosmetics do not replace medical diagnosis or treatment. A professional stockist relationship and brand training do not create a statutory competence standard for managing disease.

Mechanism of action#

Retinaldehyde sits one conversion step from retinoic acid; retinol requires conversion to retinaldehyde first. Retinyl retinoate is a different ester. Conversion sequence alone does not create a finished-product potency ladder because concentration, stability, delivery and tolerance also matter.[7, 8, 9, 12]

The 11.5-fold in-vitro conversion-rate result supports a biochemical distinction between retinal and retinol in cultured-cell extracts, not a clinical speed promise.[12]

Commonly misstated claims#

“Retinal acts 11 times faster than retinol”

The number is a conversion-rate ratio in cell-free keratinocyte extracts, not time to visible human outcome.[6, 12]

Supported statement: retinal converted to retinoic acid about 11.5 times faster than retinol in one in-vitro enzyme model.

“Retinol is capped at 0.3% throughout the UK”

The cap is EU law. Great Britain had not adopted it by August 2026.[1][2]

Supported statement: EU limits apply to named retinol substances; GB currently diverges and Northern Ireland requires separate checking.

“Crystal Retinal must be reformulated because of the EU cap”

The regulation names retinol, retinyl acetate and retinyl palmitate, not retinaldehyde.[1, 6]

Supported statement: Crystal Retinal falls outside that specific vitamin A restriction on its face.

“Medik8 products have independent peer-reviewed trials”

Its commissioned product studies are unpublished, while the published papers it cites test ingredient models or other formulations.[6, 11, 12, 13]

Supported statement: Medik8 uses commissioned product data and named ingredient literature; no peer-reviewed Medik8 product trial was located.[no source found]

Areas of remaining uncertainty#

  • The L'Oréal transaction completion date is not evidenced by the UK PSC register; this prevents stating final ownership without qualification.
  • Medik8's commissioned protocols and full results are unavailable; this makes their bias and effect sizes unassessable.
  • The reason Intelligent Retinol was unavailable is unstated; this prevents attributing it to EU reformulation.
  • No evidence compares Crystal Retinal 0.24% with tretinoin or lower retinal strengths; this limits potency and tolerance claims.
  • GB may later adopt EU vitamin A restrictions; this means the current jurisdictional difference requires monitoring.

Frequently asked questions#

Is Medik8 medical-grade?

No legal GB category called medical-grade exists. Medik8 describes itself as a cosmetics company.[2, 6]

Is retinal proven 11 times faster clinically?

No. The multiple comes from an in-vitro conversion assay.[12]

Does the EU retinol cap cover retinaldehyde?

Not by the substances named in the regulation.[1]

Are Medik8's studies published?

The product and CSA studies are not. The brand does cite published ingredient and retinyl-retinoate papers.[11][13, 12, 6]

What schedule applies?

The current product instructions govern. Skinipedia does not publish a generic regimen.

References#

Each source is graded by evidence tier. Tier 4 material (manufacturer documents, expert consensus, practitioner experience) is useful for protocol and context, and is never presented as equivalent to independent clinical evidence.

  1. Commission Regulation (EU) 2024/996 of 3 April 2024 amending Regulation (EC) No 1223/2009 of the European Parliament and of the Council as regards the use of Vitamin A, Alpha-Arbutin and Arbutin and certain substances with potential endocrine disrupting properties in cosmetic products. OJ L, 2024/996, 4.4.2024.Tier 1Supports: Full text fetched and read. Recital 2: the SCCS opinion adopted 24-25 October 2022 concluded vitamin A 'is safe in cosmetic products up to concentrations of 0,05 % Retinol Equivalent (RE) in body lotion and 0,3 % RE in other leave-on and rinse-off products', adding that the cosmetic contribution 'although low, may be of concern for consumers with the highest exposure to vitamin A (5 % of the total population) from food and food supplements'. Recital 3 sets the resulting restriction. The Annex III entry covers exactly three named substances: Retinol (CAS 11103-57-4/68-26-8), Retinyl Acetate (CAS 127-47-9) and Retinyl Palmitate (CAS 79-81-2) — retinaldehyde and retinyl retinoate are NOT listed. Labelling column, verbatim: 'For any cosmetic product containing Retinol, Retinyl Acetate or Retinyl Palmitate the following, labelling is obligatory: "Contains Vitamin A. Consider your daily intake before use"'. Footnote (*3), attached to the vitamin A entries, verbatim: 'From 1 November 2025 cosmetic products containing that substance and not complying with the conditions shall not be placed on the Union market. From 1 May 2027 cosmetic products containing that substance and not complying with the conditions shall not be made available on the Union market.' Recital 20 explains the long transition: 'there are no immediate health concerns for those substances, since their use concentrations in cosmetic products currently available on the market do not exceed the concentrations that the SCCS considers safe'. SCOPE LIMIT: this is EU law and binds the Union market only; it has no direct effect in Great Britain.
  2. The Cosmetic Products Regulation (EC) No 1223/2009 (Restriction of Chemical Substances) (Amendment and Transitional Provisions) (No. 2) Regulations 2026 (SI 2026/109), and the sibling instruments SI 2026/23, SI 2025/901, SI 2025/413, SI 2024/1334 and SI 2024/455.Tier 1Supports: Four of these instruments were opened and read directly. SI 2026/109 adds 13 CMR category 1B/2 substances to Annex 2 (effective 23 March 2027) and restricts hexyl salicylate in Annex 3 (effective 15 August 2026); it does not mention retinol, retinyl acetate, retinyl palmitate or vitamin A. SI 2026/23 prohibits 3-(4'-methylbenzylidene)-camphor from 15 July 2026, adds 16 further CMR substances from 15 August 2026, and drops the formaldehyde-releaser warning threshold from 0.05 to 0.001; it does not mention vitamin A. SI 2025/901 restricts only oxybenzone/benzophenone-3. SI 2025/413 restricts only methyl salicylate. CONCLUSION SUPPORTED: as at 1 August 2026 the assimilated Cosmetic Products Regulation as it applies in Great Britain contains no restriction on retinol, retinyl acetate or retinyl palmitate, and no mandatory 'Contains Vitamin A' warning. SCOPE LIMIT: SI 2024/455 and SI 2024/1334 were identified in the legislation.gov.uk index but not opened individually; their titles and the absence of any vitamin A entry in the later 2025-2026 instruments make a 2024 GB vitamin A restriction very unlikely but this was not directly verified.
  3. Companies House register, MEDIK8 LIMITED, company number 03783618 — company overview, persons with significant control, and filing history. Also GLOBE BIDCO LIMITED, company number 13070972.Tier 1Supports: Register consulted 1 August 2026. MEDIK8 LIMITED, company number 03783618, private limited company, status Active, incorporated 7 June 1999, registered office 730 Centennial Avenue, Centennial Park, Elstree, Herts WD6 3SZ, SIC 20411 (manufacture of soap and detergents). Previous names: PANGAEA DIRECT LIMITED (7 Jun 1999 - 14 Dec 2004), PANGAEA LABORATORIES LIMITED (14 Dec 2004 - 28 Nov 2023). PSC record: Mr Elliot James Isaacs (d.o.b. June 1971, British), ownership of shares and voting rights 75%+ plus right to appoint/remove directors, notified 6 April 2016, CEASED 20 February 2021. Active PSC: Globe Bidco Limited (company 13070972), same 75%+ categories, notified 20 February 2021, no cessation recorded. Globe Bidco Limited is itself controlled by Globe Midco 2 Limited (13069449) since 8 December 2020. Filing history: Elliot James Isaacs terminated as director 27 February 2023; name change certificate 28 November 2023; charge 037836180004 satisfied in full 18 September 2025; accounting reference date extended from 30 September to 31 December 2025 (filed 25 September 2025); group accounts for the year ended 31 December 2025 filed 6 June 2026; confirmation statement made 3 July 2026 'with no updates'. SCOPE LIMIT: no filing recording a transfer of control to L'Oréal appears on the register as at this date; the register lags real-world transactions and a share transfer between holding companies need not appear on this company's own record.
  4. L'Oréal Groupe. 'L'Oréal Groupe to acquire a majority stake in Medik8' (press release, 9 June 2025); and L'Oréal Luxe Division brand page for Medik8.Tier 4Supports: Press release states L'Oréal has signed an agreement to acquire a majority stake in Medik8; Inflexion 'remain[s] a minority shareholder'; the founder 'will continue to serve on the board, with the current management committee also remaining in place'; the brand joins the Luxe Division; 'The transaction is expected to be completed in the next few months after regulatory approvals and other customary conditions.' Describes 'a diversified omni-channel sales mix across the most prominent online and offline retailers in Europe, with a growing presence in the US'. The separate L'Oréal Luxe brand page (https://www.loreal.com/en/luxe-division/medik8/) states the brand was established in 2009 by UK scientist Elliot Isaacs, describes the CSA Philosophy as 'vitamin C and sunscreen by day, and vitamin A by night', positions Medik8 as '#1 Retinal Serum Worldwide' and as a B Corp certified British brand that originated in the professional channel. SCOPE LIMIT: neither page states a completion date; the press release itself does not disclose price. Widely reported enterprise value figures (c. EUR 1bn / c. USD 1.1bn) come from press coverage, not from this primary source, and were not independently verified.Funding / interest: Corporate communication issued by L'Oréal Groupe, the acquiring party. Every figure and characterisation serves the acquirer's narrative.
  5. Inflexion Private Equity. 'L'Oréal to acquire majority stake in Medik8' (news item, 2025).Tier 4Supports: States Medik8 was 'Founded in 2009 by British scientist Elliot Isaacs'; that Inflexion invested four years before the June 2025 announcement (consistent with the 20 February 2021 PSC date on Companies House); that during Inflexion's ownership the business tripled both headcount and sales, increased US revenue share sevenfold and achieved a six-times increase in direct-to-consumer sales; and that 'Inflexion will retain a minority shareholding in Medik8'.Funding / interest: Published by Inflexion, the selling majority shareholder. The growth figures are self-reported deal marketing, unaudited and unattributed to any accounting basis.
  6. Medik8 (medik8.com), brand-owned pages consulted 1-2 August 2026: 'CSA Philosophy' (also the int.medik8.com mirror), 'Consumer & Clinical Trials', the Vitamin A collection, the Intelligent Retinol product page and its Outlet listing, 'Professional Explained' and 'Become a Medik8 Stockist'.Tier 4Supports: RE-FETCHED AND RE-READ 2 August 2026. CSA Philosophy page: the regime is trademarked (CSA Philosophy(R)) and described as 'using vitamin C plus sunscreen in the morning and vitamin A (also known as retinol/retinal) at night', presented as '3 simple steps'; headline claims are '96% agreed their skin looked younger' and '97% agreed the CSA regime transformed their skin' (footnote 1: 'Proven via independent study on a Medik8 CSA regime, on 30 participants over 12 months'), '60% clinical improvement on all signs of skin ageing' (footnote 2: 'Based on average change in key indicators of skin ageing, in a clinical study on 63 participants using a CSA skincare regime over 12 months'), the regime addresses '90% of anti-ageing skincare needs' (footnote 3: primary biological and environmental factors, excluding cleansing), and retinal is 'proven to act 11 times faster than traditional retinol' — footnote 4 for which cites 'G. Siegenthaler et al., Retinol and retinal metabolism, Biochemical Journal, 1990, 268, pp 371-378'. IMPORTANT CORRECTION TO EARLIER DRAFT: that figure is NOT unsourced; see source 12 for what the cited paper actually measured. Consumer & Clinical Trials page lists cohort sizes product by product: Liquid Peptides Advanced MP n=34 (instrumental), Liquid Peptides n=60 (consumer self-assessment), Total Moisture Daily Facial Cream n=33 (instrumental), C-Tetra Advanced n=32 (self-assessment), Daily Radiance Vitamin C n=50 (consumer self-assessment), Super C Ferulic n=32 (instrumental, 12 weeks), CSA regime n=30 over 12 months (self-assessment), Advanced Night Restore n=53 (self-assessment), Hydr8 B5 Intense n=32 (instrumental); each is labelled 'independent clinical study' or 'independent consumer study' with no laboratory, protocol, registration or publication identified. Vitamin A collection: Crystal Retinal 1 (0.01% retinal), 3 (0.03%), 6 (0.06%), 10 (0.1%), 20 (0.2%), 24 (0.24%); Crystal Retinal Ceramide Eye 3/6/10 at 0.03%/0.06%/0.1%; r-Retinoate Intense, Day & Night and Day & Night Eye Serum (retinyl retinoate, strengths not stated); Intelligent Retinol 3TR 0.3%, 6TR 0.6%, 10TR 1% retinol, plus Intelligent Retinol Smoothing Night Cream at 0.2% retinol and Intelligent Retinol Eye TR (strength not stated). Intelligent Retinol product page on the UK site showed 'Not available for purchase' with an 'Email me when back in stock' option for all three serum strengths when accessed; the separate 'Intelligent Retinol 10TR (Outlet)' listing (£33, reduced from £55) was also sold out. Same page, verbatim: 'As a cosmetics company, we are unable to provide product advice in relation to medical conditions such as pregnancy or breastfeeding. We strongly recommend discussing the ingredients with your GP or midwife before use. We do, however, generally recommend avoiding vitamin A use while pregnant or breastfeeding.' Professional Explained page: professional treatments are available through 'expert skin therapists, who are trained in advanced skin physiology and analysis', delivered through 'thousands of specialised skin clinics, medical aesthetics practices, and premium spas', including a Crystal Retinal Age-Defying Facial and pigmentation-reducing peels. Stockist page states only: 'If you're a clinic, salon, or spa interested in becoming a Medik8 stockist, click here to contact us' — no qualification, training-hours, premises or insurance criteria are published. Site search returns an 'Exo-PDRN Prismatic+' product, 'Youthful Vitality Serum with Prismatic PDRN & Triple Exosome Complex', £79, plus a page titled 'Exo-PDRN Prismatic+ Claims'. SCOPE LIMIT: an earlier draft attributed additional CSA cohorts (57, 29, 28, 50, 26, 24) and figures (50% brightness, 40% clarity, 75% redness, 20% wrinkle) to an int.medik8.com 'User & Clinical Trials: CSA' page. That URL returns 404 and the int.medik8.com CSA page's 'full trial results' link resolves to /pages/test3, a gift-card page. Those figures could not be re-verified and have been removed from this package.Funding / interest: Entirely brand-owned marketing copy published by Medik8 Limited, the seller of every product described. The word 'independent' is Medik8's own characterisation of studies it commissioned; no third-party verification of that characterisation was located.
  7. Siddiqui Z, Zufall A, Nash M, Rao D, Hirani R, Russo M. Comparing Tretinoin to Other Topical Therapies in the Treatment of Skin Photoaging: A Systematic Review. Am J Clin Dermatol. 2024 Nov;25(6):873-890. doi:10.1007/s40257-024-00893-w. PMID 39348007.Tier 1Supports: PRISMA-compliant systematic review, PubMed and Embase from inception to December 2023, 25 included studies comparing topical agents head-to-head with tretinoin; animal studies excluded. Comparators were 'greater in 7 studies, equivalent in 13 studies, and less in 3 studies' than tretinoin, and 'most studies found the comparator to be less irritating and better tolerated by patients than tretinoin'. Authors' explicit caveat: 'given that most studies comparing topical therapies with tretinoin are of poor quality and/or demonstrate bias, there is a lack of substantial evidence to support an alternative first-line therapy.' Conclusion relevant to Medik8's hero ingredient: 'given there are some data to support the efficacy of retinoid precursors, namely retinaldehyde, pro-retinal nanoparticles, and conjugated alpha-hydroxy acid and retinoid (AHA-ret), these agents can be considered a second-line option for anti-aging treatment in patients who cannot tolerate tretinoin.' SCOPE LIMIT: ingredient-class evidence only; no Medik8 product appears in this review. Affiliations re-verified 2 August 2026 via PubMed E-utilities: School of Medicine, New York Medical College, Valhalla NY, and Department of Dermatology, Metropolitan Hospital, New York NY. Indexed publication types: 'Systematic Review; Comparative Study' — the typing in this package matches the record.Funding / interest: No funding statement and no conflict-of-interest statement appears in the PubMed record retrieved (E-utilities, 2 August 2026). All six authors are US academic/hospital dermatology; no author has a disclosed commercial stake in any retinoid product. Absence of a retrieved statement is a retrieval limit, not a verified declaration of 'none'.
  8. Milosheska D, Roskar R. Use of Retinoids in Topical Antiaging Treatments: A Focused Review of Clinical Evidence for Conventional and Nanoformulations. Adv Ther. 2022 Dec;39(12):5351-5375. doi:10.1007/s12325-022-02319-7. PMID 36220974, PMCID PMC9618501.Tier 4Supports: Focused (narrative, non-systematic) review of clinical evidence for retinoids in topical antiaging. Key conclusion, verbatim: 'In general, there is a lack of evidence from properly designed clinical trials to support the claimed efficacy of the most commonly used retinoids as antiaging agents in cosmeceuticals.' Notes that retinol, retinaldehyde and retinyl palmitate are 'contained in cosmeceuticals regulated as cosmetics' and that 'Since clinical efficacy studies are not required for marketing cosmetic formulations, there are concerns about the efficacy of these retinoids'. Identifies instability, low penetration and irritation as formulation problems. POSITIVE FINDING NOT TO BE OMITTED: the same review states that 'Retinaldehyde is considered the most effective retinoid in cosmeceuticals', with a favourable activity-to-tolerance ratio — its scepticism is about the quality of the trial base, not about retinaldehyde being weak in itself. It also records that only Creidi et al. performed a comparative clinical study, in which both formulations were effective but no statistically significant differences were observed, and concludes 'Further studies are needed to evaluate the clinical efficacy of retinaldehyde in various cosmetic formulations.' SCOPE LIMIT: narrative/focused review with no stated search protocol, PRISMA framework or risk-of-bias assessment — tier 4, not a systematic review.Funding / interest: CORRECTED 2 August 2026 after reading the open-access full text (PMC9618501). The paper DOES carry both statements. Funding, verbatim: 'No funding was received for this study or publication of this article.' Conflict of interest, verbatim: 'Daniela Milosheska and Robert Roskar have nothing to disclose.' The earlier assertion of a disclosure gap was wrong and is withdrawn. Affiliations: Milosheska at INSLAB, Maribor, Slovenia; Roskar at the University of Ljubljana, Faculty of Pharmacy — the earlier framing omitted the university affiliation and mischaracterised the authorship as non-academic.
  9. Kim J, Kim J, Jongudomsombat T, Kim E, Suk J, Lee D, Lee JH. The efficacy and safety of multilamellar vesicle containing retinaldehyde: A double-blinded, randomized, split-face controlled study. J Cosmet Dermatol. 2021 Sep;20(9):2874-2879. doi:10.1111/jocd.13993. PMID 33569865.Tier 2Supports: Citation re-verified 2 August 2026 via PubMed E-utilities: authors, journal, 2021 Sep, volume 20, issue 9, pages 2874-2879, DOI and PMID all resolve correctly. The paper's own title describes it as 'A double-blinded, randomized, split-face controlled study' — an earlier draft of this package described it as merely 'investigator-blinded', which understated the design; corrected. n=23 Korean volunteers. Multilamellar-vesicle retinaldehyde (MLV-RAL) 0.05%/0.1% cream on one randomised side, retinol 0.05%/0.1% cream on the other, 8 weeks. Crow's-feet wrinkle depth measured with the Antera 3D system; skin hydration, elasticity, facial curved length and dermal density also assessed. Results, verbatim: 'After an 8-week application, all objective parameters, including wrinkle depth, were significantly improved in both MLV-RAL and retinol treated sides. Compared with the retinol-treated side, MLV-RAL-treated side showed a significant improvement of objective assessments except for dermal density.' No adverse events with either cream. SCOPE LIMITS: n=23, 8 weeks, Korean volunteers only, no vehicle-control arm (the comparator is an active), and the comparison is of one delivery system against another — it does not establish retinaldehyde superiority per se, nor does it involve any Medik8 product.Funding / interest: Author affiliations re-checked 2 August 2026: Yonsei University College of Medicine (Severance Hospital, Cutaneous Biology Research Institute; Scar Laser and Plastic Surgery Center, Yonsei Cancer Hospital; Yongin Severance Hospital), the Catholic University of Korea, and Global Medical Research Center, Seoul — the last a contract research organisation. No funding statement and no conflict-of-interest statement is present in the PubMed record; the Wiley full text returned HTTP 402 and could not be opened. The maker of the MLV-RAL cream is not identified in the record, so a manufacturer interest can be neither confirmed nor excluded. Treat this as unresolved disclosure, not as a declared absence of interest.
  10. Konisky H, Bowe WP, Yang P, Kobets K. The Clinical Efficacy and Tolerability of a Novel Retinaldehyde Serum with Firming Peptides to Improve Skin Texture and Signs of Photoaging. J Drugs Dermatol. 2024 Nov 1;23(11):992-997. doi:10.36849/JDD.8058. PMID 39496127.Tier 3Supports: Single-arm, uncontrolled trial of one branded product (Retinal Night Advanced 0.1% Retinal Firming Treatment, Dr. Whitney Bowe Beauty, Greenwich, CT). n=32 female subjects; 47% Fitzpatrick III-VI; 57% self-described sensitive skin. Applied 3 nights weekly to face, neck and chest for 8 weeks. Results: facial fine lines 12% visible change at week 8 (P<0.0001); chest fine lines 11% at week 2 (P=0.0005) and 19% at week 8 (P<0.0001); facial visible hyperpigmentation 19% at week 8 (P<0.0001); facial texture 5% (P=0.0078); pores 20% at week 8 (P<0.0001). Patch testing showed no sensitisation or irritation. The abstract also asserts that 'Retinaldehyde (retinal) is 10x more bioavailable than retinol' as background framing — this is not an outcome measured by the study. SCOPE LIMITS: no control or vehicle arm, no randomisation, no blinding stated, 8 weeks, n=32, all female, single product. Included here as the template for brand-sponsored retinal studies, not as evidence about Medik8.Funding / interest: Author WP Bowe is the founder of Dr. Whitney Bowe Beauty, the brand that makes and sells the tested product. This is a company-authored study of the company's own product.
  11. Barbieri JS, Rubin CB, Pham JP, Wong M. The Role of Formulation in Benzene Formation in Benzoyl Peroxide Products. JAMA Dermatol. 2025;161(4):442-444. doi:10.1001/jamadermatol.2024.6443. PMID 39937513.Tier 3Supports: Cited here for one narrow, verifiable fact about the evidence base, not for its subject matter. A PubMed E-utilities search for 'Medik8'[All Fields] on 1 August 2026 returned a count of exactly 1, and this is that record. Retrieving the full PubMed XML and grepping it shows the single occurrence of the string 'Medik8' sits inside the conflict-of-interest statement: 'Dr Wong reported... personal fees from Nip & Fab, StyleKorean, Yesstyle, NAOS, Medik8, Go-To, and Deciem for content creation... outside the submitted work.' The study itself is a quality-improvement analysis of benzene levels in over-the-counter benzoyl peroxide products stratified by wash versus leave-on, hot versus cold processing, and presence of BHT and benzoic acid; it has no bearing on Medik8's products. SCOPE LIMIT: PubMed indexes titles, abstracts, keywords and disclosure statements — a brand can be studied without being named in an indexed field, so this is strong but not absolute proof of zero indexed Medik8 trials.Funding / interest: Conflict disclosures in this paper are extensive and relevant: Dr Barbieri consulting fees from Dexcel Pharma and Honeydew Care; Dr Rubin cofounder and chief medical officer of the skincare company Fig.1; Dr Wong personal and/or consulting fees from L'Oreal, P&G, Galderma, Sephora, Unilever, Swisse, Amorepacific, Nip & Fab, StyleKorean, Yesstyle, NAOS, Medik8, Go-To, Deciem and Bondi Sands, plus grants from Croda, BASF, Elf, Neutrogena and Deciem for sponsored conferences; Dr Pham no conflicts. Re-verified verbatim 2 August 2026.
  12. Siegenthaler G, Saurat JH, Ponec M. Retinol and retinal metabolism. Relationship to the state of differentiation of cultured human keratinocytes. Biochem J. 1990 Jun 1;268(2):371-378. PMID 2163611.In vitroTier 3Supports: Added by adversarial verification, 2 August 2026. This is the paper Medik8's CSA Philosophy page footnotes for its '11 times faster than traditional retinol' claim (footnote 4 on that page cites 'G. Siegenthaler et al., Retinol and retinal metabolism, Biochemical Journal, 1990, 268, pp 371-378'). Citation resolves exactly: authors, journal, year, volume 268, issue 2, pages 371-378, PMID 2163611. WHAT IT ACTUALLY MEASURED: enzymatic conversion to retinoic acid in cell extracts from cultured human keratinocytes at different differentiation states. Differentiating cells converted retinol to retinoic acid at 4.49 pmol/h per mg protein while non-differentiated cells showed no such activity; with retinal as substrate both cell types formed retinoic acid, differentiating cells at 51.6 versus non-differentiated 14.4 pmol/h per mg protein. The ratio 51.6/4.49 is approximately 11.5, which is the arithmetic origin of the marketing figure. CRITICAL SCOPE LIMIT: this is an in-vitro enzyme-kinetics experiment on cell-free extracts of cultured keratinocytes. It is not a study in living human skin, it measures no clinical endpoint, it measures no onset time, and it does not compare finished topical formulations. Converting a metabolic conversion-rate ratio in a 1990 cell-extract assay into 'proven to act 11 times faster' on skin is a scope leap from in-vitro to in-vivo and from enzyme rate to clinical speed.
  13. Medik8. 'Clinical Studies' page (medik8.com/pages/testing-and-clinical-studies), consulted 2 August 2026.Tier 4Supports: Added by adversarial verification, 2 August 2026, because it materially qualifies the 'no named sources' line taken in the earlier draft. Medik8 self-describes here, verbatim: 'Medik8 is a cosmeceutical skincare brand. As such, we use only the best active ingredients in our formulations. We use clinical studies from trusted, ethical sources to validate what we do.' Under the heading STUDIES ON RETINYL RETINOATE it lists five named, published, peer-reviewed papers with journals: H. Kim et al., Bioorganic & Medicinal Chemistry 2008 (in-vitro synthesis and biological activity); H. Kim et al., Skin Research and Technology 2011 (11 Korean women, 12 weeks, reported as improving 22% more than a 0.075% retinol cream); H. Kim et al., British Journal of Dermatology 2010 (46 Korean women, periorbital wrinkles and roughness); H. Kim et al., Skin Research and Technology 2012 (44 Korean women, visual wrinkle grades); B. Kim et al., Tissue Engineering and Regenerative Medicine 2013 (15 acne patients, 8 weeks). SEPARATE AND DAMNING FINDING: the page carries a second heading, STUDIES ON RETINALDEHYDE, whose content simply repeats the same five retinyl retinoate studies. Medik8's own evidence page for retinaldehyde — the ingredient in its hero Crystal Retinal line and the basis of its '#1 Retinal Serum Worldwide' positioning — cites no retinaldehyde study at all. SCOPE LIMITS: the five cited papers are all small, all Korean-cohort, all on retinyl retinoate rather than retinaldehyde, and were not individually retrieved or appraised by this verification pass; they are reported here as what Medik8 cites, not as validated evidence.Funding / interest: Brand-owned page published by Medik8 Limited, which sells every product the cited studies are used to support. Medik8's relationship to the cited authors, and any funding of those studies, is not disclosed on the page.